Quick Facts

• Targeted Use: For the management of certain bacterial infections.
• Key Therapeutic Areas: Respiratory tract, urinary tract, and skin infections.

---

Farobact (faropenem) is an oral beta-lactam antibiotic used in the treatment of a range of bacterial infections. It is indicated for use in therapeutic domains such as infections affecting the respiratory tract, including both upper and lower respiratory conditions.

The medication is also utilized in the management of bacterial infections of the urinary tract and genito-urinary infections. Furthermore, it serves as a therapeutic option for patients with skin and soft-tissue infections and certain gynecological infections.

Farobact is typically employed for infections caused by susceptible microorganisms. Clinical experience suggests its benefit in treating community-acquired infections.

It is important to note that the use of this medication is reserved for specific bacterial targets and should be determined by a qualified healthcare professional.

Who Can and Cannot Use Farobact? (Official Eligibility)

The population eligibility for Farobact (Faropenem medoxomil) is strictly defined by regulatory documents, focusing on patient status, age, and pre-existing conditions.

Absolute Contraindications (Cannot Use)

Farobact is contraindicated and must not be used in individuals with a known, severe allergic reaction (hypersensitivity) to the active ingredient, Faropenem medoxomil.

Furthermore, patients with a documented history of allergy to any beta-lactam antibiotic, including penicillins, cephalosporins, or carbapenems, are also prohibited from using this medicine due to the risk of cross-hypersensitivity.

---

Restricted and Conditional Use

Population Group	Regulatory Status
Renal Impairment	Restricted Use: Requires mandatory dose reduction or extended intervals to prevent drug accumulation.
Pregnancy & Lactation	Safety Not Established: Use is not generally recommended and is only permitted if the potential benefit justifies the risk, as safety data in these populations are insufficient.
Age Groups	Adults are eligible for tablet forms. Use of the tablet in pediatric patients is not established, though specific oral suspension forms are approved for children. Older adults require caution and a lower starting dose.
Comorbidities	Conditional Use: Caution is required for patients with a history of gastrointestinal disease, atopy, or poor nutritional status.

These criteria establish the official framework for safe and appropriate use as outlined in drug labeling.

Interactions with other medicines and products

The regulatory profile for Farobact (Faropenem) primarily documents pharmacokinetic interactions that alter the plasma concentration of either Faropenem or a co-administered medicine.

---

Documented Exposure-Altering Interactions

Substance	Pharmacokinetic Outcome	Regulatory Context
Probenecid	Increases Faropenem Plasma Concentration	Probenecid inhibits the active renal tubular secretion of Faropenem, leading to reduced clearance and higher systemic exposure.
Valproic Acid or Sodium Valproate	Decreases Valproate Plasma Concentration	Based on regulatory warnings for the related beta-lactam class, co-administration is noted to cause a rapid, significant decrease in Valproate serum levels.

---

Other Official Interaction Status

Interactions with Food

The official pharmacokinetic data indicate that co-administration of Faropenem with a meal results in no clinically significant difference in the overall exposure or maximum concentration of the drug.

Contraindicated Combinations and Timing Rules

No medicinal products are formally listed as contraindicated for co-administration in regulatory documents for Faropenem. Additionally, no mandatory dose timing separation rules are explicitly stated in the prescribing information. The interaction profile is primarily concerned with exposure modifications related to renal clearance.

How Farobact Works: Mechanism of Action

Farobact contains Faropenem, an orally active beta-lactam antibiotic belonging to the penem class. Its mechanism of action is focused on the irreversible inhibition of bacterial cell wall synthesis.

Faropenem is a bactericidal agent that achieves its effect by binding selectively to and inactivating Penicillin-Binding Proteins (PBPs), particularly PBP-2 and PBP-1A in certain Gram-negative organisms like Escherichia coli. PBPs are crucial bacterial transpeptidases that catalyze the final cross-linking step of peptidoglycan polymer chains, a process necessary for maintaining the structural integrity and rigidity of the cell wall.

By acting as an inhibitor of these transpeptidases, Faropenem prevents the formation of the robust peptidoglycan mesh layer. This molecular disruption leads to the accumulation of cell wall precursors and compromises the structural barrier, ultimately triggering osmotic instability and subsequent bacterial cell lysis and dissolution. Furthermore, the molecule exhibits intrinsic stability against many beta-lactamase enzymes.

Official Administration Guidelines for Farobact (Faropenem Medoxomil)

Farobact (faropenem medoxomil) is designated for oral administration only, typically provided as tablets or an oral dry syrup in certain regions. Its usage is established through specific parameters defining the appropriate route, dose, and frequency to maintain therapeutic levels.

---

Feature	Standard Instruction
Route of Administration	Exclusively oral
Standard Adult Dose	Typically ranges from 150 mg to 300 mg per dose. The maximum daily dose is often cited as 900 mg
Frequency Pattern	Administered twice daily (BID) or three times daily (TID) for standard-release formulations
Course Duration	The standard course of treatment is typically between 7 and 10 days.
Timing Relative to Meals	Doses are generally instructed to be taken with or immediately after food to enhance the absorption of faropenem medoxomil and minimize gastrointestinal effects.
Pediatric Dosing Rule	The recommended pediatric dose is 15 mg/kg of body weight per day, divided into three doses, often using the oral dry syrup formulation.
Renal Adjustment Rule	Dose reduction is indicated for patients with reduced kidney function (creatinine clearance <50 mL/min); for severe impairment, a dose of 200 mg once daily is a common adjustment.
Tablet Administration	Tablets must be swallowed whole and should not be crushed, broken, or chewed.

---

The structure of these instructions describes a protocol for use: the drug is taken by mouth in a specific milligram quantity and at a fixed frequency over a defined course length. The requirements to take the medicine with food and the necessary dose modifications for kidney function are integral parts of the administration guidelines, standardizing the medicine’s use.

Research evidence / Overview of studies for Farobact

This section provides a summary of the official clinical research and scientific studies that have explored the evaluation of Farobact (Faropenem), focusing on the types of evidence that exist and what researchers have observed so far. This overview is based on peer-reviewed scientific literature and authoritative sources.

---

Evidence for use in Specific Infections

Research has explored its use primarily through Randomized Controlled Trials (RCTs) and comparative studies against other antibiotics. These studies monitored outcomes related to symptom resolution (Clinical Cure) and improvement (Clinical Response) for conditions like Respiratory Tract Infections (RTIs) and Urinary Tract Infections (UTIs). For UTIs, researchers also monitored the measurement of pathogen clearance. Findings describe patterns observed in these studies during short-term follow-up periods. The evidence base for Skin and Soft Tissue Infections (SSTIs) is limited, with one major regulator determining that a single trial was inadequate evidence for a complete assessment.

---

Evidence in Special Populations

Farobact’s evaluation has been explored in distinct patient groups, specifically including the pediatric population (infants and children ge 6 months). These were typically observational or comparative studies focusing on RTIs and UTIs. Findings contribute to understanding symptom patterns in these specific age groups. However, the data for certain groups remain insufficient, and follow-up durations were limited, meaning the results apply only to the populations studied.

---

Long-Term Durability and Uncertainty

The research landscape is largely composed of studies designed to assess short-term outcomes over defined treatment intervals, with post-therapy assessments typically lasting up to 14 or 21 days. The long-term effects are not fully established, and there is limited information regarding the durability of the initial response. Furthermore, systematic reviews indicate that the overall number of high-quality RCTs is limited across all indications. In addition, in vitro studies described patterns related to the potential for cross-resistance to other critical antibiotics, such as carbapenems, a specific area where continued surveillance is needed.

Key Studies & References

1. Clinical Efficacy and Safety of Faropenem for the Treatment of Children with Community-Acquired Respiratory Tract Infections, Acute Otitis Media, and Urinary Tract Infections: A Systematic Review

Common questions about Farobact (FAQ)

Q: How quickly should I expect Farobact to start working?

Studies on how the body processes the medicine (pharmacokinetics) indicate that the peak concentration of the active ingredient, Faropenem, in the blood is typically reached within approximately 1 to 2 hours after administration. This indicates when the highest level of the medicine is typically measured in the blood.

Q: Are there any documented long-term effects of using Farobact?

Official research summaries indicate that studies on this medicine have primarily focused on short-term outcomes over defined treatment periods. Therefore, the official body of evidence suggests that the long-term effects are not fully established and are an area that remains under review.

Q: Can Farobact interact with supplements like iron or calcium?

Official drug interaction summaries for Farobact do not specifically list interactions with common mineral supplements like iron or calcium. However, for many antibiotics, separating the timing of administration between the medicine and mineral supplements is often noted to maintain consistent exposure levels for the medicine.

Q: Can I stop taking Farobact if my symptoms improve early?

Official administration guidelines establish a standard course duration for this medicine, which is typically 7 to 10 days. These official documents define the use of the medicine as a mandatory protocol for a defined course length, which reflects the duration studied and deemed appropriate to achieve its intended effect.

Q: Is Farobact considered safe for use during pregnancy, according to official sources?

The official regulatory status indicates that the safety of use is not established during pregnancy and lactation. Use is not generally recommended and is only permitted when regulatory documentation indicates the potential benefits are judged to outweigh the potential risks.

Q: Is Farobact suitable for children?

The medicine's eligibility differs by the form. While the tablet form is generally intended for adults, official administration guidelines confirm that specific oral dry syrup forms are approved for use in the pediatric population in certain regions.

Q: Can Farobact interact with common over-the-counter pain relievers?

Official regulatory documents do not list common over-the-counter pain relievers, such as acetaminophen or ibuprofen, as having documented interactions with Farobact. Interactions that alter the medicine's concentration are primarily noted for medications that affect how the body clears the drug.

Q: Why is Farobact sometimes prescribed when other antibiotics haven't worked?

Official descriptions of the medicine highlight its chemical stability against certain bacterial defense enzymes known as beta-lactamases. This characteristic supports its pharmacological activity against bacterial strains that may exhibit resistance to other agents.

Q: What kind of research has been done on Farobact?

Official research summaries indicate that studies have primarily included Randomized Controlled Trials (RCTs) and comparative studies. These trials focused on outcomes such as the resolution of symptoms (known as Clinical Cure) in patients being treated for infections like those in the Respiratory Tract and Urinary Tract.

Q: Is Farobact the same kind of antibiotic as penicillin?

Farobact is classified as a Penem antibiotic, which places it within the broader beta-lactam family—the same family as penicillin. However, the medicine has a unique structure, and official contraindications prohibit its use in patients with a known severe allergy to penicillins due to a potential risk of cross-hypersensitivity.

Q: Is it common to feel tired while taking Farobact?

Official regulatory safety documents, which classify possible adverse reactions, do not list tiredness or fatigue among the commonly or less commonly reported side effects of the medicine.

Q: Does Farobact affect the 'good' bacteria in the gut?

Like other antibiotics, the medicine has been associated with a risk of Clostridium difficile-associated diarrhea (CDAD), which is a severe gastrointestinal condition. This condition arises due to the disruption of the normal, protective bacterial balance in the gut.

Q: Is a metallic taste in the mouth a possible side effect of Farobact?

An altered or metallic taste in the mouth is not listed among the officially documented common or less common side effects found in the regulatory safety profile for this medicine.

Q: How long does Farobact stay in the system after the last dose?

Pharmacokinetic data indicate that the amount of the active ingredient, Faropenem, is rapidly reduced in the body. The time it takes for the concentration of the medicine to be cut in half (known as the half-life) is reported to be approximately 0.9 hours.

Q: Is Farobact used to treat skin infections?

Research has explored the medicine's use for Skin and Soft Tissue Infections (SSTIs). However, official research summaries indicate that the existing evidence base from the studies performed was determined to be inadequate for a complete assessment for this specific indication by at least one major regulator.

Q: Is Farobact available in different forms (e.g., tablet, liquid)?

The medicine is typically provided as tablets for oral administration in adults. Additionally, an oral dry syrup (a liquid suspension) is available in certain regions, which is often used for the pediatric patient population.

Q: Do studies suggest Farobact resistance is a growing concern?

Official research evidence notes the need for continued surveillance regarding the potential for cross-resistance to other critical antibiotics, such as carbapenems. This is an area that systematic reviews indicate requires continued surveillance by researchers.

Q: Why is the duration of Farobact treatment usually limited?

While the official course is mandated to be short (typically 7 to 10 days), this limitation is consistent with general antibiotic guidelines, which emphasize the use of a defined course length to minimize the potential for developing antibiotic resistance.

Q: Is Farobact manufactured by multiple companies?

The active ingredient, Faropenem, is available in the market under several generic equivalents in regions where the medicine is approved. This means the medicine may be sold under different brand names and is not limited to a single manufacturer.

Q: Are there specific symptoms that warrant immediate contact with a healthcare provider while using Farobact?

Official safety documents highlight the risk of severe and potentially life-threatening conditions, including severe hypersensitivity reactions (anaphylaxis) and severe Clostridium difficile-associated diarrhea (CDAD). These are listed as safety considerations that require awareness, as noted in the official product information.

Q: What is the evidence supporting Farobact's effectiveness?

Official research has supported the medicine's use by exploring it through randomized trials. These studies monitored outcomes related to symptom resolution (Clinical Cure) and improvement (Clinical Response) for specific conditions like Respiratory Tract and Urinary Tract Infections.

Q: What does 'use conditions' mean in relation to Farobact?

'Use conditions' refer to the officially defined administration protocol, such as the frequency and timing relative to meals, and the mandatory eligibility criteria. This includes restrictions such as age limitations or the required dose adjustments for patients with reduced kidney function.

Q: What research is available on Farobact's use in children versus adults?

Research has explored the evaluation of the medicine in both the pediatric population (infants and children ge 6 months) and adults. These studies, which were often observational or comparative, focused on how the medicine affects these distinct age groups when treating conditions such as Respiratory Tract and Urinary Tract Infections.

Q: Does Farobact need a special prescription?

Farobact is officially categorized as a prescription-only drug in jurisdictions where it is approved. This status means the medicine requires a valid prescription from a licensed healthcare provider before it can be dispensed.

Q: Does Farobact affect blood sugar levels?

The official safety profile of Farobact does not commonly list disturbances to blood sugar levels (glucose) as a reported adverse reaction or side effect.

Q: Is it possible to be allergic to Farobact if I'm not allergic to penicillin?

The official contraindication is for individuals with a known allergy to the active ingredient, Faropenem medoxomil itself. While use is prohibited for those with penicillin allergies (due to cross-hypersensitivity risk), an allergy to the specific Faropenem molecule can occur even without a prior history of penicillin allergy.

Q: Are there any official warnings about driving or operating machinery while on Farobact?

Official safety information recognizes the potential for rare adverse effects on the central nervous system, including the risk of seizures. Patients should be aware of these potential effects and the common side effect of headache when considering driving or operating complex machinery.

Q: Does Farobact have a generic version available?

The active ingredient, Faropenem, is available in the market under several generic equivalents in regions where the medicine is approved. The availability of a generic version means the medicine may be supplied by various companies.

How to Store and Dispose of Farobact (Faropenem Medoxomil)

Storage and disposal must strictly adhere to regulatory standards to maintain the medicine's stability and prevent environmental contamination.

Storage Requirements

Farobact tablets must be stored at mathbfcontrolled room temperature, typically mathbfbelow 30 C (86°F). It is mandatory to mathbfkeep the product in its original container and mathbftightly closed to mathbfprotect from light and moisture. The medicine mathbfmust not be frozen or stored in excessive heat.

Child Safety: Like all prescription medicines, Farobact must be stored mathbfout of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Farobact must be disposed of according to mathbflocal regulations and mathbfmust not be disposed of via wastewater (such as flushing down the sink or toilet). The mathbfpreferred method of disposal is through a community drug mathbftake-back program or an authorized collection site.